Related Experiment Video
Updated: Sep 28, 2025

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
Published on: June 6, 2025
Using a System Pharmacology Method to Search for the Potential Targets and Pathways of Yinqiaosan against COVID-19
Li-Hua Cao1, Xing-Yuan Jia2, Hong-Juan He1
1Academy of Chinese Medical Sciences, Henan University of Chinese Medicine, Zhengzhou 450046, Henan Province, China.
Insights
Traditional Chinese Medicine's Yinqiaosan (YQS) shows promise for treating COVID-19 pneumonia. System pharmacology identified active compounds and key pathways, revealing anti-inflammatory and antioxidative mechanisms for effective therapeutic intervention.
Area of Science:
- Pharmacology and Traditional Chinese Medicine (TCM)
Background:
- Coronavirus disease 2019 (COVID-19) rapidly spread globally, causing severe respiratory illnesses like pneumonia.
- Traditional Chinese Medicine (TCM) interventions, including Yinqiaosan (YQS), have been utilized for COVID-19 pneumonia with reported efficacy.
- A comprehensive understanding of YQS's active compounds and therapeutic mechanisms against COVID-19 pneumonia is lacking.
Purpose of the Study:
- To investigate the active compounds and therapeutic mechanisms of Yinqiaosan (YQS) in treating COVID-19 pneumonia using system pharmacology.
Main Methods:
- Employed a system pharmacology approach, including drug-likeness assessment, oral bioavailability forecasting, virtual docking, and network analysis.
- Identified active compounds, potential targets, and key molecular pathways associated with YQS treatment for COVID-19 pneumonia.
Main Results:
- Identified 117 active compounds in YQS and 77 potential targets relevant to COVID-19 pneumonia.
- YQS may treat COVID-19 pneumonia and its complications (atherosclerosis, nephropathy) via pathways including Kaposi sarcoma-associated herpesvirus infection and AGE-RAGE signaling.
- Key molecular targets identified include TNF, GAPDH, MAPK3, MAPK1, EGFR, CASP3, MAPK8, mTOR, IL-2, and MAPK14; notable compounds possess anti-inflammatory and antioxidative properties.
Conclusions:
- Systematic network pharmacology effectively predicted the active compounds, targets, and pathways of YQS for COVID-19 treatment.
- The study provides a comprehensive clarification of YQS's mechanism of action in managing COVID-19 pneumonia and associated conditions.
Abstract:
The first reported case of coronavirus disease 2019 (COVID-19) occurred in Wuhan, Hubei, China. Thereafter, it spread through China and worldwide in only a few months, reaching a pandemic level. It can cause severe respiratory illnesses such as pneumonia and lung failure. Since the onset of the disease, the rapid response and intervention of traditional Chinese medicine (TCM) have played a significant role in the effective control of the epidemic. Yinqiaosan (YQS) was used to treat COVID-19 pneumonia, with good curative effects. However, a systematic overview of its active compounds and the therapeutic mechanisms underlying its action has yet to be performed. The purpose of the current study is to explore the compounds and mechanism of YQS in treating COVID-19 pneumonia using system pharmacology. A system pharmacology method involving drug-likeness assessment, oral bioavailability forecasting, virtual docking, and network analysis was applied to estimate the active compounds, hub targets, and key pathways of YQS in the treatment of COVID-19 pneumonia. With this method, 117 active compounds were successfully identified in YQS, and 77 potential targets were obtained from the targets of 95 compounds and COVID-19 pneumonia. The results show that YQS may act in treating COVID-19 pneumonia and its complications (atherosclerosis and nephropathy) through Kaposi sarcoma-related herpesvirus infection and the AGE-RAGE signaling pathway in diabetic complications and pathways in cancer. We distinguished the hub molecular targets within pathways such as TNF, GAPDH, MAPK3, MAPK1, EGFR, CASP3, MAPK8, mTOR, IL-2, and MAPK14. Five of the more highly active compounds (acacetin, kaempferol, luteolin, naringenin, and quercetin) have anti-inflammatory and antioxidative properties. In summary, by introducing a systematic network pharmacology method, our research perfectly forecasts the active compounds, potential targets, and key pathways of YQS applied to COVID-19 and helps to comprehensively clarify its mechanism of action.
More Related Videos
07:58Behavioral and Network Pharmacology-Based Analyses for the Traditional Mongolian Medicine Zadi-5 in a Rat Model of Depression
Published on: February 24, 2023
10:21Author Spotlight: Streamlining Protein Target Prediction and Validation via Molecular Docking and CETSA
Published on: February 23, 2024